Skip to main content
Journal cover image

Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States.

Publication ,  Journal Article
Misakian, AL; Kelley, CE; Sullivan, EA; Chang, JJ; Singh, G; Kokosa, S; Avila, J; Cooper, H; Liang, JW; Botzheim, B; Quint, M; Jeevananthan, A ...
Published in: J Clin Endocrinol Metab
August 7, 2025

CONTEXT: Guidelines for use of injectable estradiol esters (valerate [EV] and cypionate [EC]) among transgender and gender-diverse (TGD) individuals designated male at birth vary considerably, with many providers noting supraphysiologic serum estradiol concentrations based on current dosing recommendations. OBJECTIVES: This work aimed to 1. determine the dose of injectable estradiol (subcutaneous [SC] and intramuscular [IM]) needed to reach guideline-recommended estradiol concentrations for TGD adults using EC/EV; 2. describe the relationship between estradiol concentration relative to timing/dose of last estradiol injection and other covariates; and 3. determine dosing differences between IM/SC EV/EC. METHODS: A cross-sectional retrospective study was conducted across 6 US medical centers including TGD adults on same-dose injectable estradiol for more than 75 days, with confirmed timing of estradiol concentration relative to last injection, from January 1, 2019 to December 31, 2023. Descriptive statistics were used to describe patient characteristics and weighted linear mixed models to evaluate relationship between various covariates and estradiol concentration. RESULTS: Data from 562 patients were included. Among those injecting every 7 days who reached the guideline-recommended estradiol concentration (n = 131, 27.5%), the median estradiol dose was 4.0 mg (interquartile range, 3.0-5.0 mg). Among all patients, the majority reached supraphysiologic estradiol concentrations (>200 pg/mL [>734 pmol/L]) while dose and timing in the injection cycle were significant covariates for the estradiol concentration. There were no significant dosing differences between IM/SC EV/EC. CONCLUSION: Injectable estradiol esters effectively reach guideline-recommended estradiol concentrations but at lower doses than previously recommended. Estradiol concentrations are best interpreted relative to timing of last injection. Route of administration and type of ester do not significantly affect estradiol concentrations.

Duke Scholars

Published In

J Clin Endocrinol Metab

DOI

EISSN

1945-7197

Publication Date

August 7, 2025

Volume

110

Issue

9

Start / End Page

e2898 / e2907

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Transgender Persons
  • Retrospective Studies
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Injections, Intramuscular
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Misakian, A. L., Kelley, C. E., Sullivan, E. A., Chang, J. J., Singh, G., Kokosa, S., … Ariel, D. (2025). Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States. J Clin Endocrinol Metab, 110(9), e2898–e2907. https://doi.org/10.1210/clinem/dgaf015
Misakian, Aaron L., Carly E. Kelley, Erika A. Sullivan, Julia J. Chang, Gagandeep Singh, Sarah Kokosa, Jonathan Avila, et al. “Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States.J Clin Endocrinol Metab 110, no. 9 (August 7, 2025): e2898–2907. https://doi.org/10.1210/clinem/dgaf015.
Misakian AL, Kelley CE, Sullivan EA, Chang JJ, Singh G, Kokosa S, et al. Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States. J Clin Endocrinol Metab. 2025 Aug 7;110(9):e2898–907.
Misakian, Aaron L., et al. “Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States.J Clin Endocrinol Metab, vol. 110, no. 9, Aug. 2025, pp. e2898–907. Pubmed, doi:10.1210/clinem/dgaf015.
Misakian AL, Kelley CE, Sullivan EA, Chang JJ, Singh G, Kokosa S, Avila J, Cooper H, Liang JW, Botzheim B, Quint M, Jeevananthan A, Chi E, Harmer M, Hiatt L, Kowalewski M, Steinberg B, Tausinga T, Tanner H, Ho TF, Mark B, Zenger B, Hu S, Gebregzabheir A, Penny JM, Loeb DF, Strickland T, Iwamoto SJ, Rothman MS, Hamnvik O-PR, Ariel D. Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States. J Clin Endocrinol Metab. 2025 Aug 7;110(9):e2898–e2907.
Journal cover image

Published In

J Clin Endocrinol Metab

DOI

EISSN

1945-7197

Publication Date

August 7, 2025

Volume

110

Issue

9

Start / End Page

e2898 / e2907

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Transgender Persons
  • Retrospective Studies
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Injections, Intramuscular
  • Humans
  • Female